Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer

This study has been terminated.
(Lack of accrual)
New York Presbyterian Hospital
Weill Medical College of Cornell University
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center Identifier:
First received: June 10, 2009
Last updated: March 4, 2015
Last verified: March 2015
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: May 2011
  Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)